Table 8.
Vaccine applications of fourth-generation poxvirus-based vectors generated by the deletion of poxviral genes.
| Poxvirus Strain | Target Pathogen or Disease | Heterologous Antigen | Status | References |
|---|---|---|---|---|
| Viral infections | ||||
| NYVAC | PRV | Glycoprotein, gB or gD glycoproteins, gII, gIII and/or gp50 glycoproteins | preclinical | [483,489,490,491,492,493,494] |
| CDV | F and HA | preclinical | [440,441,442] | |
| EHV | gene 64 | preclinical | [455] | |
| JEV | prM, E, NS1 | clinical | [456,457] | |
| HIV/AIDS | SIVK6W Env-Gag-Pol, SHIV89.6P Env, SIVmac239 Gag-Pol-Nef | preclinical | [487,495,496,497] | |
| Env (clade B) | preclinical | [411] | ||
| clade C trimeric soluble gp140(ZM96), clade C Gag(ZM96)-Pol-Nef(CN54) as VLPs | preclinical | [498] | ||
| Env, Gag-Pol-Nef (clade C) | clinical | [499,500,501,502,503] | ||
| Env, Gag-Pol-Nef (clade B) | clinical | [504,505] | ||
| AIV | HA | preclinical | [408] | |
| HTLV-1 | Env, Env + Gag | preclinical | [458,506,507] | |
| Parasitic diseases | ||||
| NYVAC | Malaria | LSA-1, CS | preclinical | [508] |
| CS, SSP2, LSA1, MSP1, SERA, AMA1, Pfs25 | clinical | [509] | ||
Abbreviations: PRV: Pseudorabies virus; AIV: Avian influenza virus; CDV: Canine distemper virus; EHV: Equine herpes virus; JEV: Japanese encephalitis virus; HTLV-1: Human T cell leukemia/lymphoma virus type 1; F: Fusion protein; HA: Hemagglutinin; CS: Circumsporozoite protein; SSP2: Sporozoite surface protein 2; LSA-1: Liver stage antigen 1; MSP1: Merozoite surface protein 1; SERA: Serine repeat antigen; AMA1: Apical merozoite antigen 1.